ClinicalTrials.gg
RecruitingNCT05358379Updated Nov 20, 2026

A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma

A Phase 1/2 interventional study of THT140 in Solid Tumor, Adult Lymphoma, sponsored by Tethra Biosciences Inc.. Recruiting at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Tethra Biosciences Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Nov 20, 2026Site recruiting status changedPrimary completion moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
330
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,910 studies in Lymphoma with a site in United States — 161 open to participants now, 288 under way, 15 of them phase 3. Lymphoma · United States.

Planned enrollment
77th of 1,595
330 · median 36
Started
2022
with 44 others
Phase 1/2
218 of 1,910
22 open now
Primary completion
2028-11
later than 218 of 281 live
Registered
1,735th of 1,910
by date

Among the 1,910 studies in Lymphoma with a site in United States, this one is the 77th largest by planned enrollment of the 1,595 interventional ones that give a count, is one of 45 that started in 2022, is one of 218 in phase 1/2, reaches primary completion later than 218 of the 281 other live ones, and was the 1,735th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

161 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,910 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.

Read the detailed description

Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations.

Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:

Group 1: Bladder cancer

Group 2: Breast cancer: Triple-negative breast cancer (TNBC)

Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])

Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC)

Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC

Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL)

Group 7: T-cell lymphoma (cutaneous T-cell lymphoma [CTCL] and peripheral T-cell lymphoma [PTCL])

Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers

03

Conditions studied

  • Solid Tumor, Adult Lymphoma

Browse trials for

Keywords

  • Bladder, Breast, Lung, Biliary tract, Colon, Lymphoma, ARID1A
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged ≥ 18 years.
  2. Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists

    1. For Phase 1, all tumor types may be enrolled
    2. For Phase 2, subjects will be enrolled as per the study design section above
  3. performance status of 0-2.
  4. Subjects who post-autologous or post- transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute
  5. Women of (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.
  6. Subjects must be able to swallow and retain orally administered medication and not have any GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
  7. Able to agree to and sign the and to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
  2. Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-19.
  3. Subjects with a history of another primary , other than:

    1. In situ carcinomas, e.g., breast, cervix, and prostate
    2. Locally excised nonmelanoma skin cancer
    3. No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
  4. Any other acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.
  5. Diseases that significantly affect GI absorption of THT140.
  6. Subjects who have impaired cardiac function or clinically significant cardiac disease.
  7. Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
  8. Presence of an active infection requiring intravenous antibiotics
  9. Presence of known history of -1/2 with uncontrolled viral load and on medications that may interfere with metabolism
  10. Presence of active virus (HBV) or virus (HCV).
  11. Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.
  12. Major surgery/surgical therapy for any cause within 4 weeks of the first dose
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Phase 1 Dose Escalation

    Phase 1 = THT140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.

    Drug: THT140

  • Experimental
    Phase 2

    Phase 2 = Recommended THT140 phase 2 dose and schedule administered orally in 28-day cycles.

    Drug: THT140

Interventions

  • DrugTHT140

    THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.

    Also known as: Plogosertib

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose

    The incidence rate of dose-limiting toxicities (first cycle only) at each dose level

    Time frame: 6 months

  2. Overall Response Rate (ORR)

    Assessment of response criteria according to RESIST, Lugano or mSWAT.

    Time frame: 18 months

Secondary outcomes

  1. Adverse events

    Type, frequency, and severity of adverse drug reactions

    Time frame: 24 months

  2. AUC

    THT140 plasma concentrations

    Time frame: 6 months

  3. Cmax

    THT140 plasma concentrations

    Time frame: 6 months

  4. Tmax

    THT140 plasma concentrations

    Time frame: 6 months

  5. T1/2

    THT140 plasma concentrations

    Time frame: 6 months

  6. Disease Control Rate

    To evaluate the disease control rate (DCR) in subjects receiving THT140.

    Time frame: 24 months

  7. Duration of Response

    To evaluate the duration of response (DOR) in subjects receiving THT140.

    Time frame: 24 months

  8. Progression-free Survival

    To evaluate progression-free survival (PFS) in subjects receiving THT140.

    Time frame: 24 months

  9. Overall Survival

    To evaluate overall survival (OS) in subjects receiving THT140.

    Time frame: 24 months

Other outcomes

  1. Pharmacodynamics

    Pharmacodynamic response to THT140 will be assessed by mRNA sequencing of blood samples to determine differential expression of PLK1 target genes (including MYC, PLK1, CDKN1A) relative to baseline.

    Time frame: 6 months

  2. Pharmacogenomics

    Genomic alterations will be assessed by next generation sequencing (NGS) at baseline and various time points during treatment with THT140 in order to investigate the relationship between genetic alterations in THT140 related pathways and response to THT140. Parameters of genetic variations (DNA mutations) and copy number variations using plasma cell-free DNA derived from peripheral blood will be assessed.

    Time frame: 24 months

07

Study locations

3 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Nov 2028, 79 months after the start.

Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 87. This study's planned 79 months is above that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Aug 2025 → Nov 2028 and completion Nov 2025 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
May 3, 2022
StartActual
Apr 14, 2022
Primary completionEst.
Nov 2028was Aug 2025
CompletionEst.
May 2029was Nov 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed. Hospital Universitario Vall d'Hebron is now Not yet recruiting
Show 2 added (2 United States)
  • Memorial Sloan Kettering Cancer Center (MSKCC) · New York, United States
  • Fred Hutchinson Cancer Center/ University of Washington · Seattle, United States
Show 2 removed
  • City of Hope · Duarte, United States
  • UPMC Hillman Cancer Center · Pittsburgh, United States
Nov 20, 2026
Primary completion
Aug 2025→Nov 2028
Nov 20, 2026
Study completion
Nov 2025→May 2029
Nov 20, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedDiseases that significantly affect GI absorption of CYC140THT140.
Nov 20, 2026
Interventions
Added Drug: THT140; removed Drug: CYC140
Nov 20, 2026
Secondary outcomes
10 description edited
What changed in the outcomes
  • DescriptionAUC: how it is measured was reworded
  • DescriptionCmax: how it is measured was reworded
  • DescriptionDisease Control Rate: how it is measured was reworded
  • DescriptionDuration of Response: how it is measured was reworded
  • DescriptionOverall Survival: how it is measured was reworded
  • DescriptionProgression-free Survival: how it is measured was reworded
  • DescriptionT1/2: how it is measured was reworded
  • DescriptionTmax: how it is measured was reworded
  • Descriptionother outcomePharmacodynamics: how it is measured was reworded
  • Descriptionother outcomePharmacogenomics: how it is measured was reworded
Nov 20, 2026
Contact
Study contact changed: j•••@cyclacel.com→j•••@tethrabio.com; m•••@cyclacel.com→m•••@tethrabio.com. See the current contact
Nov 20, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • MD Anderson Cancer Center · Houston, United StatesContact m•••@mdanderson.org→R•••@mdanderson.org · •••4667
  • Hospital Universitario Vall d'Hebron · Barcelona, SpainContact e•••@vhio.net→M•••@vhio.net
Nov 20, 2026
Title
A Study to Investigate CYC140THT140, in Subjects With Advanced Solid Tumors and Lymphoma
Nov 20, 2026
Sponsor
Cyclacel Pharmaceuticals, Inc.→Tethra Biosciences Inc.
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    2 sites added, 2 sites removed. Hospital Universitario Vall d'Hebron is now Not yet recruiting
    Show 2 added (2 United States)
    • Memorial Sloan Kettering Cancer Center (MSKCC) · New York, United States
    • Fred Hutchinson Cancer Center/ University of Washington · Seattle, United States
    Show 2 removed
    • City of Hope · Duarte, United States
    • UPMC Hillman Cancer Center · Pittsburgh, United States
    Primary completion Aug 2025→Nov 2028
    Study completion Nov 2025→May 2029
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedDiseases that significantly affect GI absorption of CYC140THT140.
    Secondary outcomes 10 description edited
    What changed in the outcomes
    • DescriptionAUC: how it is measured was reworded
    • DescriptionCmax: how it is measured was reworded
    • DescriptionDisease Control Rate: how it is measured was reworded
    • DescriptionDuration of Response: how it is measured was reworded
    • DescriptionOverall Survival: how it is measured was reworded
    • DescriptionProgression-free Survival: how it is measured was reworded
    • DescriptionT1/2: how it is measured was reworded
    • DescriptionTmax: how it is measured was reworded
    • Descriptionother outcomePharmacodynamics: how it is measured was reworded
    • Descriptionother outcomePharmacogenomics: how it is measured was reworded
    Interventions Added Drug: THT140; removed Drug: CYC140
    Sponsor Cyclacel Pharmaceuticals, Inc.→Tethra Biosciences Inc.
    Contact Study contact changed: j•••@cyclacel.com→j•••@tethrabio.com; m•••@cyclacel.com→m•••@tethrabio.com. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • MD Anderson Cancer Center · Houston, United StatesContact m•••@mdanderson.org→R•••@mdanderson.org · •••4667
    • Hospital Universitario Vall d'Hebron · Barcelona, SpainContact e•••@vhio.net→M•••@vhio.net
    Title A Study to Investigate CYC140THT140, in Subjects With Advanced Solid Tumors and Lymphoma
    + 4 other changes: verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05358379
Lead sponsor
Tethra Biosciences Inc.
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Apr 14, 2022
Primary completion
Nov 2028 (estimated)
Completion
May 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Mark H Kirschbaum, MD
Contact
mark.kirschbaum@tethrabio.com
626-316-3394
Jason Summa
Contact
jason.summa@tethrabio.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion